Significance of the gleason scoring system after neoadjuvant hormonal therapy

G. Bentley, J. Dey, W. A. Sakr, D. P. Wood, J. E. Pontes, David Grignon

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Neoadjuvant hormonal therapy (NHT) induces morphologic changes in prostate adenocarcinoma that result in the assignment of higher Gleason scores on average than in pretreatment biopsy specimens. This outcome has led to the recommendation that the Gleason scoring system not be applied to prostate adenocarcinoma specimens after NHT. We reviewed the radical prostatectomy specimens of 116 patients who had received NHT. Gleason scores were assigned on the post-treatment specimens by applying the usual criteria; in addition, an estimated pretreatment Gleason score was assigned on the basis of knowledge of the morphologic alterations associated with NHT. Finally, an estimate of the degree of therapy effect was assigned: little or no evidence of hormonal effect (grade 1) to marked therapy-related changes (grade 3). Both the post-treatment and the estimated pretreatment Gleason score correlated significantly with biochemical progression (P = 0.03 and P = 0.03, respectively; log-rank test). The degree of therapy effect did not correlate with progression (P = 0.46; log-rank test). This limited analysis suggests that despite the morphologic alterations induced by NHT, post-treatment Gleason score remains a significant prognostic measure. Further studies in more uniformly treated populations are required to confirm this observation.

Original languageEnglish (US)
JournalMolecular Urology
Volume4
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Neoplasm Grading
Prostate
Adenocarcinoma
Therapeutics
Prostatectomy
Biopsy
Population

ASJC Scopus subject areas

  • Urology

Cite this

Bentley, G., Dey, J., Sakr, W. A., Wood, D. P., Pontes, J. E., & Grignon, D. (2000). Significance of the gleason scoring system after neoadjuvant hormonal therapy. Molecular Urology, 4(3).

Significance of the gleason scoring system after neoadjuvant hormonal therapy. / Bentley, G.; Dey, J.; Sakr, W. A.; Wood, D. P.; Pontes, J. E.; Grignon, David.

In: Molecular Urology, Vol. 4, No. 3, 2000.

Research output: Contribution to journalArticle

Bentley, G, Dey, J, Sakr, WA, Wood, DP, Pontes, JE & Grignon, D 2000, 'Significance of the gleason scoring system after neoadjuvant hormonal therapy', Molecular Urology, vol. 4, no. 3.
Bentley, G. ; Dey, J. ; Sakr, W. A. ; Wood, D. P. ; Pontes, J. E. ; Grignon, David. / Significance of the gleason scoring system after neoadjuvant hormonal therapy. In: Molecular Urology. 2000 ; Vol. 4, No. 3.
@article{632390751ff1403b8081ffd04a64b5f7,
title = "Significance of the gleason scoring system after neoadjuvant hormonal therapy",
abstract = "Neoadjuvant hormonal therapy (NHT) induces morphologic changes in prostate adenocarcinoma that result in the assignment of higher Gleason scores on average than in pretreatment biopsy specimens. This outcome has led to the recommendation that the Gleason scoring system not be applied to prostate adenocarcinoma specimens after NHT. We reviewed the radical prostatectomy specimens of 116 patients who had received NHT. Gleason scores were assigned on the post-treatment specimens by applying the usual criteria; in addition, an estimated pretreatment Gleason score was assigned on the basis of knowledge of the morphologic alterations associated with NHT. Finally, an estimate of the degree of therapy effect was assigned: little or no evidence of hormonal effect (grade 1) to marked therapy-related changes (grade 3). Both the post-treatment and the estimated pretreatment Gleason score correlated significantly with biochemical progression (P = 0.03 and P = 0.03, respectively; log-rank test). The degree of therapy effect did not correlate with progression (P = 0.46; log-rank test). This limited analysis suggests that despite the morphologic alterations induced by NHT, post-treatment Gleason score remains a significant prognostic measure. Further studies in more uniformly treated populations are required to confirm this observation.",
author = "G. Bentley and J. Dey and Sakr, {W. A.} and Wood, {D. P.} and Pontes, {J. E.} and David Grignon",
year = "2000",
language = "English (US)",
volume = "4",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Significance of the gleason scoring system after neoadjuvant hormonal therapy

AU - Bentley, G.

AU - Dey, J.

AU - Sakr, W. A.

AU - Wood, D. P.

AU - Pontes, J. E.

AU - Grignon, David

PY - 2000

Y1 - 2000

N2 - Neoadjuvant hormonal therapy (NHT) induces morphologic changes in prostate adenocarcinoma that result in the assignment of higher Gleason scores on average than in pretreatment biopsy specimens. This outcome has led to the recommendation that the Gleason scoring system not be applied to prostate adenocarcinoma specimens after NHT. We reviewed the radical prostatectomy specimens of 116 patients who had received NHT. Gleason scores were assigned on the post-treatment specimens by applying the usual criteria; in addition, an estimated pretreatment Gleason score was assigned on the basis of knowledge of the morphologic alterations associated with NHT. Finally, an estimate of the degree of therapy effect was assigned: little or no evidence of hormonal effect (grade 1) to marked therapy-related changes (grade 3). Both the post-treatment and the estimated pretreatment Gleason score correlated significantly with biochemical progression (P = 0.03 and P = 0.03, respectively; log-rank test). The degree of therapy effect did not correlate with progression (P = 0.46; log-rank test). This limited analysis suggests that despite the morphologic alterations induced by NHT, post-treatment Gleason score remains a significant prognostic measure. Further studies in more uniformly treated populations are required to confirm this observation.

AB - Neoadjuvant hormonal therapy (NHT) induces morphologic changes in prostate adenocarcinoma that result in the assignment of higher Gleason scores on average than in pretreatment biopsy specimens. This outcome has led to the recommendation that the Gleason scoring system not be applied to prostate adenocarcinoma specimens after NHT. We reviewed the radical prostatectomy specimens of 116 patients who had received NHT. Gleason scores were assigned on the post-treatment specimens by applying the usual criteria; in addition, an estimated pretreatment Gleason score was assigned on the basis of knowledge of the morphologic alterations associated with NHT. Finally, an estimate of the degree of therapy effect was assigned: little or no evidence of hormonal effect (grade 1) to marked therapy-related changes (grade 3). Both the post-treatment and the estimated pretreatment Gleason score correlated significantly with biochemical progression (P = 0.03 and P = 0.03, respectively; log-rank test). The degree of therapy effect did not correlate with progression (P = 0.46; log-rank test). This limited analysis suggests that despite the morphologic alterations induced by NHT, post-treatment Gleason score remains a significant prognostic measure. Further studies in more uniformly treated populations are required to confirm this observation.

UR - http://www.scopus.com/inward/record.url?scp=0033756260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033756260&partnerID=8YFLogxK

M3 - Article

C2 - 11062366

AN - SCOPUS:0033756260

VL - 4

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 3

ER -